Adolor Faces R&D Setbacks, One With Entereg
This article was originally published in The Pink Sheet Daily
Executive Summary
Adolor discontinues development of alvimopan to treat chronic opioid bowel dysfunction after unsuccessful partnering discussions; it will proceed with the preclinical compound ADL7445.
You may also be interested in...
Nektar Starts Major Push In Opioid-Induced Constipation Space
Biotechs that manage solid proof of concept in the challenging but potentially high-value area of opioid-induced constipation might find a receptive partnering audience in a variety of pharma quarters
Nektar Starts Major Push In Opioid-Induced Constipation Space
Biotechs that manage solid proof of concept in the challenging but potentially high-value area of opioid-induced constipation might find a receptive partnering audience in a variety of pharma quarters
Niche, Lackluster: Two Words That Sum Up 2008 NME Launches
The year 2008 won't go down as the bleakest for new molecular entity drug launches. After all, FDA did approve 24 novel biologics and new molecular entities in 2008, more than in any of the three years prior